Cerebral small vessel disease (CSVD), which significantly increases the danger of stroke and cognitive disorders, is estimated to affect greater than 5 million people in France alone. In the absence of a cure, prevention of cardiovascular risk aspects stays probably the most effective strategy today. However, promising latest treatment options are being explored.
Cerebral small vessel disease is a chronic condition that affects the smallest arteries within the brain, which repeatedly supply deep areas essential for memory, attention and coordination.
Over time, these vessels turn into harder, thicker, or more fragile and permeable. The consequences of this example aren’t unusual, as cerebrovascular disease can result in paralysis, cognitive disorders, difficulty walking, in addition to lack of independence.
In France, cerebrovascular disease is estimated to affect greater than 5 million people aged 65 years or older. To date, there isn’t a treatment available to treat it.
on the Laboratory of Cardiovascular Disease Biology in Bordeaux, under the direction of Thierry Coffnahl, and Vascular Brain Health Institute (Founded by Stephanie Debate, who’s now director. Brain and Spine Institute), we try to realize a greater understanding of the origin of the disease. Here’s what we currently learn about it.
A disease that’s difficult to detect.
When the small arteries that offer the brain are affected by cerebral small vessel disease, the brain receives less oxygen and fewer nutrients than it needs.
In addition, they contribute to the formation of cells lining these blood vessels. Blood brain barrier (BBB), a structure essential for brain health. This barrier normally acts as a highly selective filter between the blood and the brain. When it becomes more permeable, unwanted substances can enter the brain tissue and contribute to its gradual deterioration.
Cerebral small vessel disease is commonly silent in its early stages. It’s common for it to go on for years with none noticeable symptoms, and the primary signs of its presence could be subtle: slow considering and balance disorders, cognitive fatigue, or unusual forgetfulness. It can even result in paralysis.
To detect this, brain magnetic resonance imaging (MRI) remains to be the reference tool today. This makes it possible to look at characteristic lesions, sometimes present before the primary symptoms, comparable to microbleeds, lacunae (small cavities that indicate previous small vessel damage), and above all White substance hyperintensitiesin other words abnormalities that reflect chronic damage to brain tissue.
As a reminder, white matter, which makes up about half of the brain’s volume, is the part that corresponds to the network of nerve fibers. These fibers could be seen as ‘highways’ that allow electrical signals to travel between different areas of the brain.
Treatments are still very limited.
To date, no drugs have been developed specifically to treat cerebral small vessel disease. However, lesions could be detected years before symptoms appear, and their progression could be slowed by early management of cardiovascular risk aspects.
Certain diseases, comparable to diabetes, heart disease, or chronic kidney disease, are known to advertise malformation of small vessel lesions within the brain.
No systematic screening is currently planned, mainly because diagnosis relies mainly on MRI, an expensive test that’s difficult to increase to the whole population.
Doctors mainly deal with aspects that scientific research has shown can affect the danger of developing the disease, including hypertension, diabetes, and cholesterol, in addition to smoking and physical inactivity.
Although prevention is very important, it does circuitously goal the biological mechanisms underlying damage to the brain’s small blood vessels.
These mechanisms aren’t yet well understood, however the major hypotheses proposed to clarify the event of the disease include dysfunction of cells inside blood vessels (endothelial cells), disruption of the blood-brain barrier, chronic inflammation and oxidative stress. This latter phenomenon, which could be in comparison with “biological rust”, regularly damages the blood vessels.
It is precisely at this level that our research is concentrated. Our recent work provides latest insights into disease mechanisms, opening latest therapeutic approaches.
A brand new approach: protecting blood vessels from the within
To higher understand cerebral small vessel disease, we undertook to dissect its mechanisms on the cellular and molecular levels. Our desire is to maneuver from preventative medicine to medicine that may directly repair and protect the brain’s microvessels.
Our research has identified a promising goal called TRIM47 (TRIPartite Motif containing 47). We have shown that this protein plays a protective role in endothelial cells by maintaining vascular integrity and limiting the consequences of oxidative stress.
The protective motion of TRIM47 appears to act through certainly one of the body’s Important antioxidant defense systemNRF2 signaling pathway. When this pathway works properly, the cell prompts its repair and detoxing mechanisms.
However, various research findings suggest that the effectiveness of this protective response decreases with age, making cells more vulnerable to oxidative stress.
We at the moment are trying to find out to what extent this mutation contributes to the event of cerebral small vessel disease and what genetic or environmental aspects may influence it.
The goal isn’t any longer simply to treat symptoms, comparable to lowering blood pressure, but to strengthen the natural defense mechanisms of the cerebral blood vessels. The goal is to treat the disease at its source, before paralysis or cognitive impairment begins.
To achieve this, one approach into consideration is to extend the activity of the TRIM47/NRF2 pathway, and subsequently the antioxidant pathway, in hopes of preserving the blood-brain barrier and protecting neurons.
Two complementary strategies are currently being explored: developing latest molecules that concentrate on this protective pathway or repurposing existing drugs that may act on these mechanisms.
Targeting messenger RNA for disease therapy
Our first therapeutic strategy involves targeting messenger RNA (mRNA), a molecule that acts as a form of “assembly blueprint” for protein production inside cells, to cut back protein production.
KEAP1.
Indeed, KEAP1 inhibits the activity of the TRIM47/NRF2 cellular protection system. By removing this blockage, we hope to strengthen the natural defenses of the cerebral blood vessels against the aging and degenerative processes.
To achieve this goal, we’re developing molecules referred to as antisense oligonucleotides (ASOs), that are designed to specifically recognize KEAP1 messenger RNA and reduce its expression. These ASOs are chemically modified to enhance their stability inside the body and promote their delivery to cerebral blood vessels and brain cells.
Identifying probably the most effective therapeutic sequence for this highly precise task, optimizing its chemical properties and route of administration, after which confirming that it effectively reaches its goal within the brain before evaluating its ability to preserve vascular health and brain function are essential.
To translate this biological discovery into potential treatments, we’re working with teams of chemists in Bordeaux. European Institute of Chemistry and Biology and Nucleic Acids: Laboratory of Natural and Artificial RegulationExperts within the design and composition of RNA targeting molecules.
This close collaboration between biologists and chemists is crucial to progress from an understanding of a fundamental biological mechanism to the event of advanced drug candidates which might be more targeted, simpler, and potentially higher tolerated.
Repurposing existing drugs
There is one other promising path. To test drugs that are already on the market for other indications.comparable to multiple sclerosis, and that are known to cross the blood-brain barrier and activate the NRF2 pathway, a mechanism related to antioxidant and anti inflammatory protective effects.
This strategy, referred to as drug repurposing, offers a significant advantage: it will probably save years of research since the compounds have already got established human safety data.
As a result, if clinical studies in a research laboratory prove successful, clinical trials in patients could be initiated rather more quickly than could be possible for a completely latest drug.
This will make it possible to offer latest treatment options to patients faster while also reducing research and development costs.
Hope after brain aging
For the primary time, latest therapeutic strategies may finally make it possible to directly goal a few of the mechanisms involved in cerebral small vessel disease, a number one explanation for age-related cognitive decline.
This research remains to be at an early stage, and a number of other phases of validation shall be required before any application in humans could be considered.
The belief that guides our research is that by protecting the brain’s blood vessels, we also protect memory, independence and quality of life. Better treatment of cerebral small vessel disease could ultimately mean fewer strokes, less dependency, and more years of healthy life.
While waiting for targeted therapies to turn into available, certain measures have already shown their effectiveness in maintaining mental health: controlling blood pressure, engaging in regular physical activity, avoiding tobacco, eating a balanced weight-reduction plan, and maintaining an lively social and mental life.
These are easy recommendations, but they’re one of the effective ways to offer long-term protection for the brain.